NCT03188783View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

August 9, 2017

Study Completion Date

August 9, 2017

Conditions
Healthy Volunteer
Interventions
DRUG

GDC-0853

GDC-0853 tablets orally, either a single dose or twice-daily.

DRUG

Placebo

GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.

Trial Locations (1)

90630

West Coast Clinical Trials, Cypress

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03188783 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants | Biotech Hunter | Biotech Hunter